Science Daily, recently reported on new findings regarding neuroimaging and an increased ability to ‘see’ Alzheimer’s disease at its earliest stage. As you’ve read here before, earlier diagnosis will ultimately to improved treatment, possibly slowing the progression of the disease.

Researches at UCLA followed 169 study participants diagnosed with Mild Cognitive Impairment (MCI), the stage between the cognitive decline associated with normal aging and the more serious changes associated with Alzheimer’s disease. Over a three year period, they took pictures of the brains of the individuals in the study, using sophisticated imaging and noting subtle changes over time.

After three years, the researches observed that the individuals who converted from MCI to Alzheimer’s disease showed changes in the hippocampus of the brain, specifically a 10-30 percent atrophy. The early changes noted in the brain imaging appeared before participants reported any decrease in functional ability related to Alzheimer’s disease.

Lianna Apostolova, senior author, of the study’s related paper and a member of the UCLA Laboratory of Neuro Imaging stated, ““We feel this is an important finding because it is in living humans.” She went on to say, “Now we have a sensitive technique that shows the ‘invisible’ – this is, the progression of a disease before symptoms appear.”

www.nature.com/.../n1s/full/jcbfm2009170a.html

As with Alzheimer’s disease, there is no simple way to reach a diagnosis of Mild Cognitive Impairment (MCI). Individuals who notice symptoms associated with MCI, including forgetting appointments and details of recent events or conversations as well as frequently repeating conversations and information, should speak to their physician.

During the diagnostic process, one can expect to be asked a number of questions about noted changes, history of symptoms and a family health history. In addition, the physician may ask to speak with a family member or close friend, to ask about observation of symptoms.

From there, a number of tests will be conducted to eliminate other potential causes for memory loss including: a complete physical exam, blood tests, an evaluation for depression or other mental illness, brain imaging, and a neuropsychological assessment.

The process is very involved, but once completed offers a clear picture of what is causing memory changes. It is important to note that not all memory change is caused by Alzheimer’s disease. At times, memory loss may be caused by an acute condition that can be treated. Also, as researchers learn more and more about memory loss, recognition of the earliest changes in cognition will lead to the most effective treatment.

A recent study from the University of Central Florida (UCF), provides new information about the earliest stages of Alzheimer’s disease, where preventative treatment is possible.

Among scientists and many lay people, it is well known that beta-amyloid is a destructive force to nerve cells in people suffering from Alzheimer’s disease. Beta-amyloid builds up in the brain, clumping in neurons and forming damaging deposits knows as plaque. This plaque is one of the hallmarks of Alzheimer’s disease.

In the disease process, the beta-amyloid damages and eventually kills neurons, brain cells. Many research studies have focused on the damaged nerve cells in trying to understand this process towards seeking a possible prevention and treatment.

In this new study, researchers from UCF looked at smaller amounts of beta-amyloid and its effect on healthy nerve cells. The scientists found that this more moderate exposure to the beta-amyloid has an effect on the cells, preventing the normal transfer of electronic signals in the brain.

The discovery is important in that it provides evidence that changes are occurring in the brain well before there are any noted changes to memory or behavior, that is, symptoms of the disease. This information may be valuable in the quest for a treatment that works in the earliest stages of the disease, suitable for an individual with the mild cognitive impairment.

More research is needed to fully understand the role of beta-amyloid in Alzheimer’s disease as well as potential treatments.

Have you ever heard the term Mild Cognitive Impairment (MCI)?

More and more, I see this term used for the general public: to describe newsworthy findings of studies about memory and aging, in educational materials from leading organizations like the Alzheimer’s Association, and from neurologists caring for people experiencing memory loss.

MCI refers to the stage between the cognitive decline associated with normal aging and the more serious changes associated with Alzheimer’s disease, marked by progressive loss of memory and day to day functional abilities.

Researchers and scientist are particularly interested in studying people with MCI as they may be seeing Alzheimer’s disease (AD) at its earliest stage. People with MCI are an important part of research studies seeking information about biomarkers, risk factors, and prevention of AD.

Senior Living Residences, www.seniorlivingresidences, is currently implementing a number of cognitive health initiatives to help people living with the memory changes associated with MCI and the earliest stages of Alzheimer’s disease.

Visit this blog again for information on the diagnosis, treatment, and services available for people with Mild Cognitive Impairment.